434 - Doit-on continuer à traiter par Anti-VEGF les ruptures de l’épithélium pigmentaire secondaires à un traitement par Anti-VEGF ? - 23/04/09
D* PEREIRA,
I ADAM-ZUNDANE,
R ADAM,
T RODALLEC,
FX BROUSSEAUD,
JP NORDMANN
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Introduction: To evaluate cases of retinal pigment epithelium tear due to anti VEGF with or without subsequent anti VEGF treatment.
Materials and Methods: 4 cases of retinal pigment epithelium tear were evaluated in ETDRS and on OCT at 1 month distance after subsequent anti VEGF treatment and confronted to untreated retinal pigment epithelium tears. All retinal pigment epithelium tears initially occurred due to anti VEGF treatment for wet ARMD.
Results: No amelioration at ETDRS was detectable either after or without subsequent treatment. No significant amelioration was detected on OCT in the group with treatment comparing to the group without treatment. No subjective amelioration of the image was detected on the subjective evaluation scale between 0 and 4.
Discussion: Retinal pigment epithelium tears after Anti VEGF injections are not rare and their taking care is problematic. There is no available treatment of this complication, but we analyse the effect of anti VEGF in the clinical course of these tears.
Conclusion: No objective, nor subjective amelioration was detectable in this group of patients with pigment epithelium tear due to anti VEGF treatment.
© 2009 Elsevier Masson SAS. Tous droits réservés.
Vol 32 - N° HS1
P. 137 - avril 2009 Retour au numéro
Article précédent
- 433 - Ranibizumab, première ATU de cohorte en ophtalmologie.
- S* ZEROUTA, G SOUBRANE
- 435 - Injection intravitréenne de Bevacizumab ou de Ranibizumab combinée à une injection sous ténonienne de Triamcinolone dans les DMLA humides.
- I* ZUNDANE, S BRUNEAU, R ADAM, T RODALLEC, FX BROUSSEAUD, B DUFAY-DUPAR, JP NORDMANN
Bienvenue sur EM-consulte, la référence des professionnels de santé.